Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLL By Ogkologos - February 25, 2025 776 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR Loving Yourself April 7, 2021 What to Know About Navigating Your Cancer Care During An Extreme... September 27, 2023 Adding Pembrolizumab to Chemotherapy with or without Bevacizumab Improves Overall Survival... January 9, 2024 ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March March 14, 2025 Load more HOT NEWS More than 65,000 people are left waiting to find out if... Survivor Guest Post: Living Breast-less Time to get stratified Test Detects Early Signs of Remaining Cancer in Kids Treated for...
